(Z)-3-(4-chlorophenyl)-N-(4-fluorophenyl)-2-methoxyacrylamide | 1357447-87-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (Z)-3-(4-chlorophenyl)-N-(4-fluorophenyl)-2-methoxyacrylamide
• 英文别名: (Z)-3-(4-chlorophenyl)-N-(4-fluorophenyl)-2-methoxyprop-2-enamide
• CAS: 1357447-87-0
• 化学式: C₁₆H₁₃ClFNO₂
• 分子量: 305.736
• InChiKey: ZUKBLAMCQCRACU-GDNBJRDFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-(4-chlorophenyl)-2-oxopropionic acid 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 4.5h， 生成 (Z)-3-(4-chlorophenyl)-N-(4-fluorophenyl)-2-methoxyacrylamide
  参考文献：
  名称：

  Synthesis of novel cinnamanilides as potential immunosuppressive agents

  摘要：

  A series of new cinnamanilides (6-40) were synthesized and their immunosuppressive activity and cytotoxicity were evaluated. Most of the cinnamanilides showed good immunosuppressive activity. Among the synthesized compounds, (Z)-N-(4-bromophenyl)-2-methoxy-3-(4-methoxyphenyl)acrylamide (37) and (Z)-2-methoxy-3-(4-methoxyphenyl)-N-p-tolylacrylamide (38) exhibited potent immunosuppressive activity (IC50 = 1.77 +/- 0.33 and 0.94 +/- 0.13 mu M) without significant cytotoxicity. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.10.027

文献信息

• Synthesis of novel cinnamanilides as potential immunosuppressive agents
  作者：Lei Shi、Lu Wang、Zhi Wang、Hai-Liang Zhu、Qiao Song

  DOI：10.1016/j.ejmech.2011.10.027

  日期：2012.1

  A series of new cinnamanilides (6-40) were synthesized and their immunosuppressive activity and cytotoxicity were evaluated. Most of the cinnamanilides showed good immunosuppressive activity. Among the synthesized compounds, (Z)-N-(4-bromophenyl)-2-methoxy-3-(4-methoxyphenyl)acrylamide (37) and (Z)-2-methoxy-3-(4-methoxyphenyl)-N-p-tolylacrylamide (38) exhibited potent immunosuppressive activity (IC50 = 1.77 +/- 0.33 and 0.94 +/- 0.13 mu M) without significant cytotoxicity. (C) 2011 Elsevier Masson SAS. All rights reserved.